| Dr Abdel-rahman Elbash, MD | |
|
44125 Woodridge Pkwy, Suite 180, Lansdowne, VA 20176 | |
| (571) 291-2432 | |
| (703) 542-4254 |
| Full Name | Dr Abdel-rahman Elbash |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 25 Years |
| Location | 44125 Woodridge Pkwy, Lansdowne, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659542801 | NPI | - | NPPES |
| 1659542801 | Other | SC | RAILROAD MEDICARE |
| 1659542801 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 0101245181 (Virginia) | Secondary |
| 207W00000X | Ophthalmology | TL31098 (South Carolina) | Primary |
| 207W00000X | Ophthalmology | 226841 (New York) | Secondary |
| Entity Name | Loudoun Ophthalmology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275763617 PECOS PAC ID: 8224180179 Enrollment ID: O20110803000763 |
News Archive
WellCare Health Plans, Inc. today reported results for the first quarter ended March 31, 2010. As determined under generally accepted accounting principles, the Company reported net income of $6.4 million, or $0.15 per diluted share, compared with a net loss of $36.9 million, or $0.89 per diluted share, for the prior year period. Adjusted net income for the first quarter of 2010 was $7.4 million, or $0.17 per diluted share, as compared with $12.3 million, or $0.29 per diluted share, for the same period in 2009.
Patients with colon cancer who used multivitamins during and after being treated with post-surgical chemotherapy did not reduce the risk of the cancer returning or their dying from it, according to researchers at Dana-Farber Cancer Institute.
Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.
Despite the deaths of two people among the thousands treated with a promising multiple sclerosis drug, MS patients are trying to persuade the U.S. government to allow the drug back onto the market.
A cancer tumor's ability to mutate allows it to escape from chemotherapy and other attempts to kill it. So, encouraging mutations would not be a logical path for cancer researchers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Abdel-rahman Elbash, MD 44125 Woodridge Pkwy, Suite 180, Lansdowne, VA 20176 Ph: (571) 291-2432 | Dr Abdel-rahman Elbash, MD 44125 Woodridge Pkwy, Suite 180, Lansdowne, VA 20176 Ph: (571) 291-2432 |
News Archive
WellCare Health Plans, Inc. today reported results for the first quarter ended March 31, 2010. As determined under generally accepted accounting principles, the Company reported net income of $6.4 million, or $0.15 per diluted share, compared with a net loss of $36.9 million, or $0.89 per diluted share, for the prior year period. Adjusted net income for the first quarter of 2010 was $7.4 million, or $0.17 per diluted share, as compared with $12.3 million, or $0.29 per diluted share, for the same period in 2009.
Patients with colon cancer who used multivitamins during and after being treated with post-surgical chemotherapy did not reduce the risk of the cancer returning or their dying from it, according to researchers at Dana-Farber Cancer Institute.
Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.
Despite the deaths of two people among the thousands treated with a promising multiple sclerosis drug, MS patients are trying to persuade the U.S. government to allow the drug back onto the market.
A cancer tumor's ability to mutate allows it to escape from chemotherapy and other attempts to kill it. So, encouraging mutations would not be a logical path for cancer researchers.
› Verified 5 days ago
Dr. Gitanjali Bhagia Baveja, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 19441 Golf Vista Plz Ste 320, Lansdowne, VA 20176 Phone: 703-858-9800 Fax: 703-858-9801 | |
Christina Eunha Choi Chang, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 19441 Golf Vista Plz Ste 320, Lansdowne, VA 20176 Phone: 703-858-9800 | |
Lorena Sepsakos, M.D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 19441 Golf Vista Plz Ste 320, Lansdowne, VA 20176 Phone: 703-858-9800 Fax: 703-858-9801 | |
Dr. Ahmed Nasrullah, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 19415 Deerfield Ave, Ste 106, Lansdowne, VA 20176 Phone: 703-723-9633 Fax: 703-723-9772 | |
Tony Kang, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 19415 Deerfield Ave Ste 106, Lansdowne, VA 20176 Phone: 703-723-9633 Fax: 703-723-9772 | |
Mrs. Sarah Anne Merrill, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 19441 Golf Vista Plaza, Suite 320, Lansdowne, VA 20176 Phone: 703-858-9800 Fax: 703-858-9801 |